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Introduction 
Epstein-Barr virus (EBV) latent membrane 
protein 1 (LMP1), has all the typical 
characteristics of an oncogene and extensive 
studies have shown beyond doubt its abilities 
in cellular transformation giving rise to 
malignant phenotypes. NPC carcinogenesis, 
as typical as any other solid tumours, is a 
multi-step process. One of the most important 
EBV latent genes expressed in NPC is the 
viral oncogene, latent membrane protein-1 
(LMP1). Its expression is known to occur 
early in the pre-invasive stage. (Pathmanathan 
et al., 1995). Under the influence of such host 
selective pressure, this present study 
hypothesized that there exist a selection 
process in the progress from the pre-malignant 
to the malignant stages of NPC that 
culminates in the selection for the LMP1 
genotype that is expressed in the full 
malignant stage but does not compromise 
malignant growth. In other words, the 
hypothesis states that a dynamic equilibrium 
process governing the expression of LMP1 in 
NPC carcinogenesis does so by constantly 
selecting for the LMP1 genotypes that are not 
in conflict with but instead facilitate the 
progress of tumorigenesis.  
 
Materials and Methods 
 
Polymerase Chain Reaction 
DNA was extracted from throat wash 
samples collected from 120 NPC patients and 
14 healthy controls. DNA template (100 ng) 
was amplified in a total reaction volume of 50 
µL. Each reaction contained 1.25 U HotStar® 
Taq polymerase, 1 µM of each primer, 10 µM 
of each deoxynucleotide, 2 mM MgCl2 and 1× 
PCR Reaction Buffer. The primer sequence as 
well as amplification conditions and expected 
the amplimer size for each analysis are 
described in Eng-Lai et al., (2003). For Xho1 
polymorphism, the amplified PCR products 






RT was performed using the Superscript™ 
II One-step RT-PCT System following the 
manufacturer’s recommendations. Gene-
specific primers in 10 µM concentrations were 
used in a total reaction volume of 50 µL. 
Amplified product were analysed by agarose 
gel electrophoresis and fragments of the 
correct size were cloned into the pcDNA3.1 
vector.  
 
Cloning of cDNA 
cDNA of genes of interest were 
synthesized, amplified and cloned into the 
pcDNA3.1 TOPO-TA plasmid. The plasmid 
was a linearized vector with single 3’-
thymidine overhangs that facilitates efficient 
TA-cloning of PCR products which normally 
have one overhanging adenosine residue at the 
3’ ends. Due to the incorporation of a 
termination codon in the LMP1 cDNA, there 
was no fusion of the poly-histidine region at 
the C-terminus. Freshly amplified cDNA (1 
µg) was mixed with 10 ng of pcDNA3.1 
vector in a final volume of six µL reaction 
mix containing 0.2 M NaCl and 0.01 M 
MgCl2. The cloning reaction was incubated at 
room temperature for five minutes to allow for 
the insertion of cDNA into the plasmid. The 
circularized plasmid with the cDNA insert of 
interest was added into a tube containing 100 
µL of competent Escherichia coli and 
transformed by heat-shock treatment at 42°C 
for one minute. Immediately, 250 µL of SOC 
medium was added and the transformed E 
.coli was incubated in a shaking incubator at 
37°C for one hour. The E. coli transformants 
were spread onto agar plates containing the 
selection medium (LB + 100 µg/mL 
amplicillin). Plates were incubated at 37°C for 
48 hours to allow for the growth of bacterial 
colonies.  
 
Real-time Quantitative PCR 
The mRNA transcript levels of E-cadherin 
in transfected TW01 cells were quantified 
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using reverse-transcription coupled to real-
time quantitative PCR using iCycler iQ™ 
Real Time PCR system (Bio-Rad, USA). The 
quantification standards consisted of serially 
diluted pcDNA-Ecad plasmids ranging from 
1.0×102 to 1.0×107 copies in 10-fold 
increments. A five µL aliquot containing 250 
ng of RNA extracted from cells were 
subjected to reverse-transcription (RT) 
followed by conventional amplification. The 
combined RT-PCR was done using the 
TaqMan® One-Step RT-PCR Master Mix 
Reagents. E-cadherin mRNA was quantified 
using the primers, E-cadRTF and E-cadRTR, 
and detected with the TaqMan® probe. 
GAPDH was used as an internal control to 
normalize the E-cadherin transcript levels 
between different samples using primer and 
JOE-labeled probe supplied in TaqMan® 
GAPDH Control Reagents Kit. One-step RT-
PCR was performed in a 50 µL reaction 
volume that contained the following 
components; 1.25 U MultiScribe™ reverse 
transcriptase, 300 nM of each primer, 25 nM 
of TaqMan probe, 4 mM MgCl2, 200 µM of 
each dATP, dCTP and dGTP; 400 µM of 
dUTP; 0.5 U AmpErase uracil N-glycosylase 
(UNG) and 1.25 U AmpliTaq Gold. 
Amplification parameters consisted of the 
following step in sequential order; cDNA 
synthesis at 42°C for 30 minutes, UNG 
activation at 50°C for 2 minutes, initial 
denaturation at 95°C for 8 minutes, followed 
by 40 cycles of 95°C for 30 seconds and 56°C 
for 1 minutes. Amplification for each sample 
and standard was performed in duplicates. A 
standard curve was only accepted if the 
correlation coefficient is 0.996 or higher and 
its slope ranged between -3.74 to -3.32, which 
correlate to amplification efficiency of 
between 85 to 100% respectively. The 
fluorescence detection threshold value was set 
at 10× the mean standard deviation of 
fluorescence in all reactions. 
 
ELISA 
Purified and concentrated LMP1 protein 
was diluted to 2µg/mL in PBS. Each well of a 
microtitre plate was coated with 50µL of the 
diluted antigen solution. The coated plate was 
incubated for two hours at room temperature 
(RT). The coating solution was removed and 
the plate was washed twice, each time with 
300 µL PBS per well. Each well of the 
antigen-coated plate was incubated overnight 
in 300 µL blocking buffer at 4ºC. The 
following day, the plate was washed twice 
with PBS and challenged with 50 µL serum 
samples that had been diluted accordingly in 
blocking buffer (200× dilutions for IgG; 100× 
dilution for IgA), and incubated at RT for two 
hours. Negative control wells were incubated 
with 50 µL blocking buffer only. The plate 
was washed four times with PBS. The bound 
human antibody was detected by the addition 
of either 50 µL AP-conjugated goat anti-
human IgG or IgA (both diluted 2000× in 
blocking buffer) according to the 
manufacturer’s  recommendations. The plate 
was incubated at RT for two hours and 
stringently washed four times as described. 
Bound phosphatase conjugate was detected 
using Bluephos® Microwell Phosphatase 
Substrate Reagent (KPL Inc, USA: Product 
No.: 50-88-02) and the chromogen was 
allowed to develop for 30 minutes. Colour 
development was stopped by adding 100 µL 
stop solution (2.5% EDTA). Absorbance at 
630 nm was measured using an ELISA plate 
reader.  
 
Tumorigenicity in Nude Mice 
Six to eight-week-old male Balb/c nu/nu 
mice maintained in pathogen-limited 
conditions at Institute of Medical Research, 
Kuala Lumpur, Malaysia, were used 
throughout the studies. Exponentially growing 
TW01 clones with viability greater than 90% 
were used for injection. A total of 5.0×106 
cells in 200 µL RPMI-1640 medium were 
subcutaneously injected into the right flank a 
mouse using a 25-gauge needle attached to a 
1000 µL plastic syringe. Three mice were 
injected with each of the three LMP1-
expressing TW01 clones (TW01-NORLMP1, 
TW01NPCLMP1 and TW01-B95LMP1) and 
the empty vector-transfected control. All mice 
were observed weekly and tumour size was 
estimated as the product of three dimensions 
(width × length × height) and expressed as 
mm3. Final observation was done on the 
seventh week and mice that had developed 
tumours were sacrificed to have the growth 
removed. Excised tumours were immediately 
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Differential Gene Expression Assays 
The cancer related genes that were 
differentially-expressed in LMP1-expressing  
TW01 clones (in vitro study) and in and their 
resulting nude mice tumours (in vivo study) 
were investigated using the Panorama™ 
Human Cancer Oligoarray™. Each array 
comprised of two fields where each gene was 
represented by duplicate of spots. Each spot 
consisted of three 70-bp oligonucleotides for a 
particular gene. Also included on the nylon 
array were spots representing a number of 
‘housekeeping’ genes as positive controls and 
for signal normalization and non-human genes 
that served as negative controls. The signal to 
noise ratio in this array experiment was 
significantly improved by the use of Human 
Cancer cDNA Labeling primers. The labeling 
primers contained all the necessary primers 
for amplifying cDNA species that have their 




LMP1 30-bp Deletion and Xho1 
Polymorphism 
Throat washes from 120 NPC patients and 
14 healthy subjects were genotyped for the 
Xho1 polymorphism and 30-bp deletion. Of 
the 49 amplifiable NPC samples, 10 (20%) 
possessed the deletion at exon C of LMP1 
(156-bp product) whereas 38 (78%) showed 
the 30-bp retention variant (186-bp product) 
(Figure 1). One NPC sample displayed a 
deletion larger than 30-bp.  All amplimers 
from the seven throat washes of healthy 
subjects showed the retention variant. The 
primers, LMP1 and LMP-Pro2, amplified the 
Xho1 polymorphic region in exon A of LMP1 
in 21 (18%) of the 120 NPC samples. 
Following restriction digest, the 113-bp 
undigested fragments corresponding to the 
loss of Xho1 restriction site in amplimer were 
detected in 17 (81%) of the 21 samples 
(Figure 2).  All five of the throat washes 
amplifiable from the 14 healthy subjects 
retained the Xho1 restriction site and 
displayed the 67 and 46-bp digested products 








FIGURE 1 EBV LMP1 30-bp deletion analysis of 
throat wash samples. Lane 1: 100-bp molecular 
ladder. Lane 2: B95.8 control without the deletion 
(186-bp). Lane 3: AG876 control that possessed 
the 30-bp deletions (156-bp). Lanes 4 – 6: Samples 
from NPC patients with the 30-bp deletion. Lane 7: 
One NPC sample possessing a deleted fragment 
larger than 30-bp. 
 
 
FIGURE 2 Xho1 restriction digest analysis of EBV 
LMP1 from throat wash samples. Lane 1: 100-bp 
molecular ladder. Lane 2: B95.8 control that 
retained the restriction site (two bands of 67 and 
46-bp after Xho1 digestion). Lane 3 -5: NPC 
samples that displayed loss of Xho1 restriction site 
yielded the undigested 113-bp product. 
 
Antigenicity of Recombinant LMP1 Protein 
Serum samples from three study groups 
comprising of; 1) 20 untreated NPC patients, 
2) 20 healthy controls and 3) 20 NPC patients 
who had been treated by radiotherapy were 
assayed against a panel of four recombinant 
LMP1s – AGLMP1, B95LMP1, NPCLMP1 
and NORLMP1. All study groups had 
significantly higher mean IgG levels against 
NORLMP1 as compared to NPCLMP1. The 
difference in mean IgG level against these two 
LMP1 proteins was especially pronounced in 
untreated NPC patients (Figure 3). Differences 
in IgG levels between B95LMP1 and 
AGLMP1 were not significant in all three 
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study groups at the p = 0.05 level (One-way 
ANOVA). 
 
FIGURE 3 Bar charts with standard deviations 
representing mean IgG levels in three study groups 
comprising of untreated NPC patients (NPC), 
healthy controls (NOR) and treated NPC patients 
(Treated) against a panel of recombinant LMP1 
derived from type 2 EBV (AGLMP1), type 1 EBV 
(B95LMP1), malignant tissue (NPCLMP1) and 
dysplastic tissue (NORLMP1). Differences in 
mean IgA levels against the panel of four different 
recombinant LMP1 proteins were not significant in 
all three study groups. Differences in mean IgG 
levels between NORLMP1 and NPCLMP1 were 
significant and consistent in all three study groups 
(One-way ANOVA, p ≤ 0.05). 
 
Down-regulation of E-cadherin Expression 
E-cadherin was detected at 3.67×104 
copies/µg RNA in the LMP1-negative TW01 
control. However, significantly lower levels of 
E-cadherin transcripts were observed in 
LMP1-transfected cells. Of the two variants of 
LMP1 tested, the levels of E-cadherin in 
NORLMP1-transfected cells (956 copies/µg 
RNA) was 2.5 times lower than in the clone 
expressing NPCLMP1 (2360 copies/µg RNA). 
Reduction in the level of E-cadherin 
transcripts were also detected in TW01 clone 
expressing the wild-type B95LMP1 (1916 
copies/µg RNA). 
 
Tumorigenicity in Athymic Nude Mice 
Tumour volume was determined at the end 
of the seventh week. Sizable tumours with 
irregular shapes began to appear five weeks 
after inoculation in all mice inoculated with 
both the LMP1-expressing cells and the 
LMP1-negative TW01 clone. Sizes of tumour 
arising from different inoculums at the 
seventh week were at variance and on 
average, largest mean tumour volumes (132 
mm3) were observed in mice inoculated with 
the dysplastic tissue-derived LMP1 
(NORLMP1). It could be inferred that the 
contribution of LMP1 to tumorigenesis was 
negligible as the LMP1-negative control 
developed tumours in the absence of LMP1 
expression. Thus, the TW01 line was proven 
to be tumorigenic in its own right and the 
direct tumourigenic contribution of the 
different LMP1 variants tested could not be 
concluded from the observations made here.  
However, as mentioned, the variations in 
mean tumour volumes between mice injected 
with different LMP1-expressing clones were 
noteworthy.  
 
In vitro and In vivo Gene Expression Studies 
A total of 22 genes were down-regulated in 
LMP1-expressing TW01 clones irrespective 
of the LMP1 variants. Some of the known 
functions of these genes include control of cell 
proliferation (FES, TGFB1, LOC55908, 
FXYD3, BCAR1, FGFR4 and JUND), 
angiogenesis (BAI2 and ECGF1), and cellular 
differentiation (MYOG and GBX2). Some 
were structural proteins (ANK1 and ITGB4) 
and some were involved in protein transport 
and signal transduction (GNAS1, TRA1 and 
LGALS3BP). The TW01 cells expressing 
NORLMP1 had 17 genes that were up-
regulated with respect to LMP1-negative 
control and these were also specific genes in 
that they were not detected in other clones 
expressing other variants of LMP1. Nine of 
these 17 genes were also detected in the 
corresponding nude mouse tumour that 
formed after the injection of this cell clone. 
By contrast, only the 10 house-keeping genes 
were detected in TW01 clone expressing 
NPCLMP1 while all other genes detected in 
the LMP1-negative control cells were down-
regulated. TW01 clone expressing the wild-
type LMP1, B95LMP1, had 11 genes detected 
on the array, out of which, only one was up-
regulated with respect to the control. In this in 
vitro gene expression study, the TW01-
NPCLMP1 and TW01-B95LMP1 clones were 
very similar in their expression profiles based 
on the number of identical genes that were 
down-regulated with respect to the control. 
There were five genes that were down-
regulated in these two clones. Moreover, most 
of the genes up-regulated in the TW01-
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two clones. Five genes were up-regulated in 
all tumours arising from LMP1-expressing 
clones irrespective of variants.  
 
Discussion 
The identification of EBV infection in the 
pre-invasive or pre-malignant lesion 
underscored the important role of the virus in 
early tumorigenesis and the expression of the 
viral oncogene, LMP1, implicated its 
functional significance in early transformation 
events leading to malignancy. The discovery 
of sequence, anitigenic and functional 
variations in the LMP1 derived from the pre-
malignant lesion (NORLMP1) and the 
malignant lesion (NPCLMP1) implied that 
there existed a dynamic selection pressure on 
the viral oncogene during the progress of 
NPC. Of note was the differential antigenicity 
manifested by these two LMP1 variants in 
untreated NPC patients. This observation was 
consistent with the report on the dynamic 
shifts in cytotoxic T-cell epitopes that select 
for a particular LMP1 variant during the 
development of NPC. These epitope shifts 
were known to render the LMP1 non-
immunogenic (Edwards et al., 2004). The 
presence of both 30-bp deletion and Xho1 
polymorphism in both NORLMP1 and 
NPCLMP1 suggested an early selection event 
for these mutations and their specificity to 
NPC as has been demonstrated in the laser-
microdissected NPC cells. As pointed out in 
this present study, the presence of these 
mutations alone could not account for their 
manifested differences in biological functions 
important for tumorigenesis, i.e. oncogenicity, 
gene regulations and resistance to apoptosis. 
Hence the important contributions of non-
conservative point mutations that have not 
been fully addressed to date. This present 
study is the first in pursuing the notion that 
LMP1 derived from lesions of different 
histological stages are also at variant in their 
biological properties. The consequential effect 
of NORLMP1 being more antigenic and thus 
theoretically more likely to be recognized by 
the host immune system, was countered by its 
more aggressive nature of being better 
enhanced for growth in soft agar, conferred 
higher resistance to stimuli-induced apoptosis 
and more tumorigenic as it gave rise to 
relatively larger tumours in nude mice. 
Moreover, in comparison to NPCLMP1, 
NORLMP1-expressing TW01 cells regulated 
a larger number of genes in vitro and in vivo, 
again suggesting their differences in the 
intricacies of molecular interactions. The 
differential gene regulation profiles induced 
by NORLMP1 and NPCLMP1 in EBV-
negative TW01 cells were not only an 
indication of functional dissimilarities but also 
represented a molecular ‘snap-shot’ on the 
complex molecular interactions at work in the 
progress of NPC that were specifically 
regulated by different LMP1 variants. It could 
be inferred from the present study that EBV 
has culminated a successful strategy that 
enabled it to adapt to changing histological 
conditions by specifically allowing its 
oncoprotein, LMP1, to be a subject of 
selection process imposed by the tumour 
microenvironment while at the same time, 
LMP1 contributes to the success of 
tumorigenesis in ways that are most 
appropriate in a given histological stage. The 
persistence of the Xho1 polymorphism in the 
N-terminus and the C-terminal 10 aa deletion 
and their manifestation in early NPC 
suggested their roles in the early tumorigenic 
events while the point mutations were more 
likely to be responsible for determining the 
biological characteristics manifested in the 
NPC epithelial cells, TW01. The striking 
resemblance in sequence homology of 
NPCLMP1 to other reported NPC-derived 
LMP1 variants suggested the existence of 
universally conserved mutations befitting 
malignant NPC while the NORLMP1, 
expressed in the pre-malignant stage, may 
represents an intermediate variant that was of 
temporal benefit in the course to malignancy.  
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